文献速递甲状腺与浅表US

超声引导下经皮聚桂醇注射治疗囊性甲状腺结节的疗效评估及相关因素分析

Efficacy Assessment and Analysis of Related Factors of Ultrasound-Guided Percutaneous Lauromacrogol Injection for Cystic Thyroid Nodules.
PubMed 文献 · J Ultrasound Med · 2022-11-19

该回顾性研究纳入99个囊性甲状腺结节,分析超声引导下聚桂醇注射治疗的短期和长期疗效影响因素。3个月和12个月结节消退率分别为79.80%和96.91%,12个月治愈率80.41%。Tg-FNA水平是短期预后的独立因素,Tg-FNA水平和血供是长期预后的独立因素;评估3个月疗效的AUC为0.79,Tg-FNA阈值126.92 ng/mL时敏感度0.85、特异度0.70。

要点

  • 聚桂醇注射治疗囊性甲状腺结节有效,12个月治愈率80.41%。
  • Tg-FNA水平是短期和长期预后的独立因素(P<.05)。
  • 血供是长期预后的独立因素,黏稠或富血供结节疗效较差。

核心结论

  • 超声引导下经皮聚桂醇注射是囊性甲状腺结节的有效治疗选择。
  • 对黏稠或富血供的囊性为主的结节疗效较差。

研究设计与样本

  • 回顾性研究,纳入2018年7月至2021年7月间99个囊性甲状腺结节。
  • 所有结节均行超声引导下细针穿刺活检、细针穿刺洗脱液甲状腺球蛋白(Tg-FNA)检测及超声引导下经皮聚桂醇注射。
  • 术后3个月和12个月随访,分析初始体积、血供、病理类型和Tg-FNA水平与疗效的关系。

诊断标准与关键数值

  • 短期疗效:3个月体积缩小率(VRR)<50%为无效,≥50%为有效。
  • 长期疗效:12个月VRR<90%为未治愈,≥90%为治愈。
  • 3个月疗效评估的ROC曲线下面积0.79(95%CI:0.65-0.89)。
  • Tg-FNA阈值126.92 ng/mL时,特异度0.70,敏感度0.85。

临床应用与阅片要点

  • 治疗前可检测Tg-FNA水平以预测疗效,阈值126.92 ng/mL有助于识别可能疗效不佳者。
  • 评估结节血供有助于预判长期疗效,富血供结节可能需调整治疗策略。
  • 黏稠囊性结节对聚桂醇注射反应较差,应考虑其他处理方式。

局限性

  • 回顾性研究设计。
  • 单中心研究,样本量有限(99个结节)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to investigate the factors influencing the short-term and long-term efficacy of sclerotherapy for cystic thyroid nodules.

METHODS: Ninety-nine cystic thyroid nodules that underwent ultrasound-guided fine-needle aspiration biopsy, detection of thyroglobulin in fine needle aspirate (Tg-FNA), and ultrasound-guided percutaneous lauromacrogol injection were retrospectively enrolled from July 2018 to July 2021. All nodules were followed up at 3 and 12 months after the procedure. Factors related to lauromacrogol injection efficacy, including initial volume, vascularity, pathological types, and Tg-FNA level, were analyzed. The nodules were classified as non-effective (VRR <50%) and effective groups (VRR ≥50%) at 3 months to evaluate short-term prognosis, and non-cured (VRR <90%) and cured groups (VRR ≥90%) at 12 months to evaluate long-term prognosis.

RESULTS: The volume of cystic thyroid nodules tended to shrink during follow-up. The resolution rate was 79.80% (79/99) at 3 months and 96.91% (94/97) at 12 months. The cure rate was 80.41% (78/97) at 12 months. Independent factors for the long-term prognosis included Tg-FNA level and vascularity (P < .05). Only Tg-FNA level was an independent factor for the short-term prognosis (P < .05). The area under the receiver operating characteristic curve for assessing the efficacy at 3 months was 0.79 (95% confidence interval [CI]: 0.65-0.89). With a cutoff value of Tg-FNA 126.92 ng/mL, the specificity was 0.70, and the sensitivity was 0.85.

CONCLUSIONS: Ultrasound-guided percutaneous lauromacrogol injection is an effective treatment option for cystic thyroid nodules. It is less effective in viscous or vascular predominantly cystic nodules.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Gao, Dai, Wang, et al. Efficacy Assessment and Analysis of Related Factors of Ultrasound-Guided Percutaneous Lauromacrogol Injection for Cystic Thyroid Nodules. J Ultrasound Med. 2022. PMID: 36401842. doi:10.1002/jum.16123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。